JP2008526840A - 新規化合物 - Google Patents

新規化合物 Download PDF

Info

Publication number
JP2008526840A
JP2008526840A JP2007550328A JP2007550328A JP2008526840A JP 2008526840 A JP2008526840 A JP 2008526840A JP 2007550328 A JP2007550328 A JP 2007550328A JP 2007550328 A JP2007550328 A JP 2007550328A JP 2008526840 A JP2008526840 A JP 2008526840A
Authority
JP
Japan
Prior art keywords
aryl
alkyl
heterocyclyl
amino
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007550328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526840A5 (https=
Inventor
バッハ，ペーター
ボストレム，ヨナス
ブリックマン，ケイ
チェン，レイフェン
ジョルダネット，ファブリツィオ
グローンバーグ，ロバート・ディー
ハーベイ，ダーレン・マーティン
オサリバン，マイケル・エフ
ゼッターベルグ，フレドリック
エステルルンド，クリスター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0500140A external-priority patent/GB0500140D0/en
Priority claimed from GB0521484A external-priority patent/GB0521484D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2008526840A publication Critical patent/JP2008526840A/ja
Publication of JP2008526840A5 publication Critical patent/JP2008526840A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2007550328A 2005-01-06 2006-01-04 新規化合物 Pending JP2008526840A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0500140A GB0500140D0 (en) 2005-01-06 2005-01-06 Novel compounds
GB0521484A GB0521484D0 (en) 2005-10-21 2005-10-21 Novel compounds
PCT/SE2006/000010 WO2006073361A1 (en) 2005-01-06 2006-01-04 Novel pyridine compounds

Publications (2)

Publication Number Publication Date
JP2008526840A true JP2008526840A (ja) 2008-07-24
JP2008526840A5 JP2008526840A5 (https=) 2008-12-25

Family

ID=36647772

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007550328A Pending JP2008526840A (ja) 2005-01-06 2006-01-04 新規化合物

Country Status (15)

Country Link
US (1) US20090227555A2 (https=)
EP (1) EP1836189A1 (https=)
JP (1) JP2008526840A (https=)
KR (1) KR20070107024A (https=)
AR (1) AR055554A1 (https=)
AU (1) AU2006204159A1 (https=)
BR (1) BRPI0606437A (https=)
CA (1) CA2594255A1 (https=)
IL (1) IL183961A0 (https=)
MX (1) MX2007008237A (https=)
NO (1) NO20073101L (https=)
RU (1) RU2007129779A (https=)
TW (1) TW200626593A (https=)
UY (1) UY29325A1 (https=)
WO (1) WO2006073361A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012091010A1 (ja) * 2010-12-28 2012-07-05 大日本住友製薬株式会社 二環性ピリミジン誘導体
JP2024527427A (ja) * 2021-07-23 2024-07-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル グラム陰性細菌排出ポンプ阻害剤

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008101924A (ru) * 2005-07-13 2009-08-20 Астразенека Аб (Se) Новые аналоги пиридина
US20080009523A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New Pyridine Analogues IV
WO2008004945A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab Novel crystalline forms i and ii
US20080032992A1 (en) * 2006-07-04 2008-02-07 Astrazeneca Ab New Pyridine Analogues V
WO2008004944A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab Novel crystalline form ii
TW200811133A (en) * 2006-07-04 2008-03-01 Astrazeneca Ab New pyridine analogues III 334
UY30868A1 (es) * 2007-01-12 2008-09-02 Astrazeneca Ab Nuevos compuestos de piridina, composiciones farmacéuticas conteniéndolas y aplicaciones.
US20100137277A1 (en) * 2007-01-12 2010-06-03 Astrazeneca Ab Pyridine compounds and their use as p2y12 antagonists
AR064864A1 (es) * 2007-01-12 2009-04-29 Astrazeneca Ab Compuestos analogos de piridina vii 543 y composicion farmaceutica
CN101679358B (zh) * 2007-06-18 2013-10-30 塞诺菲-安万特股份有限公司 作为p2y12拮抗剂的吡咯衍生物
US20090018166A1 (en) * 2007-07-13 2009-01-15 Astrazeneca Ab New Pyridine Analogues X 161
AR074628A1 (es) * 2008-07-07 2011-02-02 Astrazeneca Ab Derivados de piridina 2- amino-6-alquil sustituidos utiles como inhibidores de p2y12 308
WO2011002067A1 (ja) * 2009-07-02 2011-01-06 武田薬品工業株式会社 複素環化合物およびその用途
WO2013033178A1 (en) 2011-08-30 2013-03-07 University Of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
TW201412728A (zh) 2012-08-21 2014-04-01 Hoffmann La Roche 新穎吡啶衍生物
GB201604970D0 (en) 2016-03-23 2016-05-04 Syngenta Participations Ag Improvements in or relating to organic compounds
WO2024121138A1 (en) 2022-12-06 2024-06-13 Idorsia Pharmaceuticals Ltd Crystalline adipic acid salt form of a ccr6 antagonist

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526178A (ja) * 1997-08-28 2001-12-18 メルク エンド カムパニー インコーポレーテッド ピロリジン系およびピペリジン系ケモカイン受容体活性調節剤
WO2003031397A1 (en) * 2001-10-05 2003-04-17 Novartis Ag Acylsulfonamides as inhibitors of steroid sulfatase

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE288444T1 (de) * 1995-05-29 2005-02-15 Pfizer Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
DK1257550T3 (da) * 2000-02-04 2006-03-27 Portola Pharm Inc Blodplade-ADP-receptor-inhibitor
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
US7132408B2 (en) * 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7018985B1 (en) * 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
FR2820057A1 (fr) * 2001-01-30 2002-08-02 Ct De Transfert De Technologie Membrane pour chambre d'encapsulation de cellules produisant au moins une substance biologiquement active et organe bio-artificiel comprenant une telle membrane
AU2002336462A1 (en) * 2001-09-06 2003-03-24 Millennium Pharmaceuticals, Inc. Piperazine and homopiperazine compounds
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
US7504497B2 (en) * 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7335648B2 (en) * 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) * 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US8071624B2 (en) * 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
US20080009523A1 (en) * 2006-07-04 2008-01-10 Astrazeneca Ab New Pyridine Analogues IV
MX2008016562A (es) * 2006-07-04 2009-02-06 Astrazeneca Ab Analogos de piridina nuevos.
US20080032992A1 (en) * 2006-07-04 2008-02-07 Astrazeneca Ab New Pyridine Analogues V

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526178A (ja) * 1997-08-28 2001-12-18 メルク エンド カムパニー インコーポレーテッド ピロリジン系およびピペリジン系ケモカイン受容体活性調節剤
WO2003031397A1 (en) * 2001-10-05 2003-04-17 Novartis Ag Acylsulfonamides as inhibitors of steroid sulfatase

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012091010A1 (ja) * 2010-12-28 2012-07-05 大日本住友製薬株式会社 二環性ピリミジン誘導体
JP2024527427A (ja) * 2021-07-23 2024-07-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル グラム陰性細菌排出ポンプ阻害剤

Also Published As

Publication number Publication date
WO2006073361A9 (en) 2007-08-02
US20090227555A2 (en) 2009-09-10
IL183961A0 (en) 2007-10-31
BRPI0606437A (pt) 2008-03-11
MX2007008237A (es) 2007-08-17
RU2007129779A (ru) 2009-02-20
UY29325A1 (es) 2006-08-31
CA2594255A1 (en) 2006-07-13
AU2006204159A1 (en) 2006-07-13
KR20070107024A (ko) 2007-11-06
EP1836189A1 (en) 2007-09-26
TW200626593A (en) 2006-08-01
US20090042852A1 (en) 2009-02-12
WO2006073361A1 (en) 2006-07-13
AR055554A1 (es) 2007-08-22
NO20073101L (no) 2007-07-19

Similar Documents

Publication Publication Date Title
US20070244088A1 (en) New Pyridine Analogues II
US20090227555A2 (en) Novel Pyridine Compounds
US20080045494A1 (en) Pyridine Analogues VI
KR20090036573A (ko) 신규한 피리딘 유사체
US20080009523A1 (en) New Pyridine Analogues IV
US20100137277A1 (en) Pyridine compounds and their use as p2y12 antagonists
US20090018166A1 (en) New Pyridine Analogues X 161
US20080200448A1 (en) New Pyridine Analogues VIII 518
US20080312208A1 (en) Pyridine Analogues
WO2008085118A1 (en) Pyridine compounds and their use as p2y12 antagonists.
US20100069350A1 (en) New Pyridine Analogues III
CN101137643A (zh) 新型吡啶化合物
CN101479256A (zh) 新的吡啶类似物
HK1124599A (en) New pyridine analogues

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081104

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120220

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120730